Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

BACKGROUND: Treatment with ipilimumab, a fully human anti-CTLA-4 antibody approved for the treatment of advanced melanoma, is associated with some immune-related adverse events (irAEs) such as colitis (gastrointestinal irAE, or GI irAE) and skin rash, which are managed by treatment guidelines. Never...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahabi, Vafa, Berman, David, Chasalow, Scott D, Wang, Lisu, Tsuchihashi, Zenta, Hu, Beihong, Panting, Lisa, Jure-Kunkel, Maria, Ji, Rui-Ru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637501/
https://www.ncbi.nlm.nih.gov/pubmed/23521917
http://dx.doi.org/10.1186/1479-5876-11-75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637501/
https://www.ncbi.nlm.nih.gov/pubmed/23521917
http://dx.doi.org/10.1186/1479-5876-11-75

Ejemplares similares